Sign in
Taking peopleNo phase

Rapidlink device for repairing aortic arch vessels during open aortic surgery

Tests the Rapidlink device in adults having open surgery for thoracic aortic disease.

Key facts

Who runs it
Vascutek Ltd.
Where
London, United KingdomSee the siteAlso in 4 other countries, 20 sites
Trial code
Registry title
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
Status
Recruiting
People taking part
150 people, planned
Started
19 Dec 2025
Expected to end
Nov 2028
Type of study
Interventional
Treatments tested
  • Rapidlink
Record updated
27 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who need open surgery on the chest part of the aorta (the main artery). During the surgery, they will get the Rapidlink device in one or more of the arch vessels.

Age
18 years or over
Sex
All sexes
Disease stage
Disease of the chest part of the aorta that needs open surgical repair with a Gelweave graft or Thoraflex Hybrid device. The target vessel (LSA, LCCA and/or IA) must have an 8-15 mm inner diameter.

Main reasons for not taking part

  • Ruptured aorta, active endocarditis or active infection of the aorta
  • Not fit enough for open surgery with circulatory arrest
  • Cannot take blood thinners or antiplatelet drugs as the protocol requires
  • Kidney failure (on dialysis or serum creatinine ≥2.5mg/dL (221 µmol/L))
  • Pregnant or planning pregnancy during the study

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Patient is aged 18 years or over on date of consent
  • Written informed consent (from patient or a legally authorized representative) to participate in study, documenting willingness and ability to comply with all study procedures and study visits (unless an exemption for emergency cases has been IRB / EC approved)
  • Patient's need for open surgical repair of the thoracic aorta using a Gelweave graft or a Thoraflex Hybrid device (AnteFlo or Plexus) in line with the applicable IFU
  • Anticipated need to use Rapidlink for the repair or replacement of the LSA, LCCA and/or IA during the open surgical repair
  • Patient has an 8-15 mm inner diameter (target SAV)
  • The diameters of the patient's target supra-aortic vessel(s), fall within the ranges specified in the IFU

Who cannot take part

  • Patient cannot receive anticoagulation / antiplatelet therapy during or after the index procedure as per the protocol
  • Patient is unfit for open surgical repair involving circulatory arrest per the study investigator
  • Patient is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study
  • Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated
  • Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure
  • Patient has a condition which may compromise or prevent the necessary imaging requirements
  • Patient has active endocarditis or an active infective disorder of the aorta
  • Patient has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure
  • Patient has an uncorrectable bleeding anomaly
  • Patient has renal failure (defined as dialysis dependent or serum creatinine ≥2.5mg/dL)
  • Patient does not have a clear landing zone equal to the implantable stent length which is free from stenosis, calcification or thrombus
  • Patient does not have a sealing zone free from tortuosity
  • Patient has significant angulation (>79° with an internal radius of less than 6mm) for the full implantable stent length
  • Patient has uncontrolled hypercoagulation
  • Patient has anatomic variants which would compromise circulation to the first branch off the target artery after placement of the Rapidlink device (unless planned and/or otherwise revascularized)
  • Patient has known sensitivity to polyester, nitinol, tantalum, or materials of bovine origin
  • Patient has a ruptured aorta
  • Patient is female and is pregnant or planning to become pregnant during the course of the study. Females of childbearing potential must use acceptable methods of contraception during the course of the study
  • Patient has a co-morbidity causing expected survival to be less than 1 year
  • Patient has a known chronic aortic dissection involving the intended landing zone of the target supra-aortic vessel(s)

Where in United Kingdom

Also in 4 other countries, 20 sites

  • St. Bartholomew's HospitalLondon, United KingdomContact: Clinical Trial CoordinatorNot yet recruiting

About the trial

What the trial wants to find out

The Goal of this Clinical Study is to evaluate the safety and effectiveness of the Rapidlink device in the repair or replacement of the supra-aortic vessels during open surgical repair of aortic disease affecting the thoracic aorta.

Read full original descriptionShow less

This study will collect information on patients who are already having surgery to repair their aorta and who will have Rapidlink device implanted into one or more of the aortic arch vessels.

The first 32 subjects enrolled will undergo left subclavian artery repair or replacement, only, with the Rapidlink device. After the 32nd subject, enrollment will proceed to include subjects undergoing any supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and/or innominate artery) repair or replacement with the Rapidlink device in a planned surgery.

After the 32nd subject is enrolled in the main group, up to 30 subjects will undergo supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and/or innominate artery) repair or replacement with the Rapidlink device in an emergency setting.

Data will be collected before, during and after surgery including recovery at discharge, 30 days, 6 months, 1 and 2 years after the surgery.

The group in the trial

  • Rapidlink DeviceTreatment being tested

    Treatment: Rapidlink

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluation of the Rapidlink Device for Use in the Repair or Replacement of the Supra-Aortic Vessels During an Open Surgical Procedure of the Thoracic Aorta
Plain-language title
Rapidlink device for repairing aortic arch vessels during open aortic surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
27 July 2026